This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks to Watch Under $5

3. Curis (CRIS - Get Report) is a drug discovery and development company engaged in developing cancer therapies. The company's advanced program is Hedgehog pathway inhibitor under collaboration with Genentech, a wholly owned member of the Roche Group.

All the nine analysts covering the stock recommend a buy on it. Its average 12-month price target is $6.07, up 33.1% from the current price, as per a Bloomberg consensus.

For the 2011 third quarter, Curis reported revenue of $0.1 million, down from $3.2 million during the 2010 period. This decrease is attributable to $3.0 million in license fee revenue, which was recorded in the 2010 third quarter, subsequent to a major payment the company received from Debiopharm during the quarter. Operating expense was maintained at $5.0 million. Net loss stood at $4.2 million, or 5 cents per share, vs. net loss of $1.5 million, or 2 cents per share, for the same period prior year.

Curis recently said that its collaborator Roche has submitted a Marketing Authorization Application (MAA) for Vismodegib (GDC-0449, RG3616) to the European Medicines Agency (EMA). During November, Curis entered into an agreement, wherein The Leukemia & Lymphoma Society (LLS) will support the company's ongoing development of its oral small molecule dual Pi3K and HDAC inhibitor CUDC-907 targeting patients with B-cell lymphoma and multiple myeloma.

Going forward, the company expects to initiate a Phase I clinical trial for an oral formulation of CUDC-101 and also a Phase I trial for new development candidate CUDC-907, a PI3K and HDAC inhibitor, during the first half of 2012. Debiopharm, the company's licensee for its Hsp90 inhibitor Debio 0932, has indicated that it plans to initiate Phase Ib studies of Debio 0932 in the near term.
3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ZQK $0.01 -10.48%
CRIS $1.32 2.30%
IMMU $2.06 4.80%
NM $0.81 -0.01%
SIRI $3.35 -0.30%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs